<DOC>
	<DOCNO>NCT00756912</DOCNO>
	<brief_summary>This study design assess safety administration 3 dose level eritoran subject undergo schedule undergo allogeneic bone marrow transplant ( BMT ) . An allogeneic BMT transplantation blood stem cell take bone marrow blood another person .</brief_summary>
	<brief_title>A Study Eritoran ( E5564 ) Administered IV Over 14 Days Prior During Bone Marrow Engraftment BMT Patients Who Have Received Myeloablative Conditioning Treatment Are Receiving Bone Marrow Stem Cells From Matched Related Donors</brief_title>
	<detailed_description>Please note : original protocol , study phase list `` Phase Ib '' , although Official Title read `` Phase I '' .</detailed_description>
	<criteria>Subjects must meet inclusion criterion outline order eligible participate study : 1 . Adult subject ( age 18 55 year old ) undergo schedule undergo myeloablative conditioning allogeneic BMT , stem cell match donor . 2 . Subjects use either busulfan total body irradiation ( TBI ) contain regimen BMT treatment malignant nonmalignant disease . For example : Cyclophosphamide Total Body Irradiation ( CYTBI ) TBI dose least 1200 cGy fractionate TBI Etoposide Total Body Irradiation ( VP16TBI ) TBI dose least 1200 cGy fractionate TBI Busulfan cyclophosphamide ( BUCY ) least 14 mg/kg busulfan orally 11.2 mg/kg busulfan intravenously ( 14 x 0.8 correction factor ) target busulfan dose strategy aim serum concentration great 600 ng/mL steady state . 3 . Leukemia patient : acute myelogenous leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) first subsequent complete remission chronic myelogenous leukemia ( CML ) first subsequent chronic phase accelerate phase myelodysplastic syndrome ( MDS ) patient . OR Subjects nonHodgkin 's lymphoma complete remission determine physical exam , CT PET scan , otherwise consider candidate allogeneic BMT judge treat institution 4 . Available match related CD34+ stem cell ( target cell dose 2 x 10^6/kg 10 x 10^6/kg ( actual body weight ) ) transplantation ( match 6/6 HLA Class I HLAA B Class II HLADRBI ) . 5 . Sex distribution : men nonpregnant woman . Women childbearing potential must negative serum βhuman chorionic gonadotropin ( hCG ) urine assay prior eritoran treatment prior begin condition treatment . Menopausal woman must amenorrheic least 12 month . 6 . Race : . 7 . Has sign inform consent studyspecific procedure perform . 1 . Unwilling unable agree fully evaluate followup visit . The subject subject 's representative study staff agree perform study assessment even subject discharge hospital . 2 . Seropositive human immunodeficiency virus ( HIV ) ; test need already perform ( documentation require ) part screen condition treatment . 3 . Subjects document possible systemic infection , suspect medically significant viral , bacterial , fungal infection begin treatment Day 3 . 4 . Have take investigational medication ( ie , approve FDA indication ) within 30day period prior enrollment study . 5 . Karnofsky Performance Status ( KPS ) &lt; 60 % . 6 . Have previously receive bone marrow stem cell transplant . 7 . Are receive Tcell deplete BMT stem cell infusion . 8 . Are pregnant lactating . 9 . Known sensitivity eritoran excipients . 10 . Prior malignancy treat curative intent &lt; 5 year allow . Previously treat cancer curative intent &gt; 5 year allow . 11 . Legal incapacity . 12 . Any following laboratory parameter within 2 day prior begin treatment Day 3 : direct bilirubin ≥ 2x ULN liver function test ( ALT AST ) value ≥ 3x ULN serum creatinine ≥ 2x ULN 13 . Subjects enrol interventional , investigational protocol . As aGvHD likely occur treatment eritoran complete , investigational treatment Grades III IV aGvHD may allow discussed Sponsor . 14 . Subjects history current pulmonary disease force vital capacity ( FVC ) force expiratory volume 1 second ( FEV1 ) &lt; 60 % predict ( correct hemoglobin ) . 15 . Subjects history cardiac ejection fraction &lt; 45 % , mark screen baseline prolongation QT/QTc interval ( QTc interval &gt; 470 mSec ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>ANC</keyword>
	<keyword>BMT</keyword>
	<keyword>graft versus leukemia</keyword>
	<keyword>graft vs. host disease</keyword>
	<keyword>MD2 ( endotoxin binding-protein )</keyword>
	<keyword>undergo allogeneic BMT</keyword>
	<keyword>myeloablative</keyword>
	<keyword>conditioning</keyword>
	<keyword>therapy</keyword>
</DOC>